Insight Molecular Diagnostics (IMDX) Payables (2020 - 2025)
Historic Payables for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.1 million.
- Insight Molecular Diagnostics' Payables rose 720.81% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 720.81%. This contributed to the annual value of $2.3 million for FY2024, which is 13913.96% up from last year.
- As of Q3 2025, Insight Molecular Diagnostics' Payables stood at $1.1 million, which was up 720.81% from $1.3 million recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Payables ranged from a high of $5.3 million in Q1 2021 and a low of $908000.0 during Q1 2024
- Its 5-year average for Payables is $2.0 million, with a median of $1.9 million in 2021.
- Per our database at Business Quant, Insight Molecular Diagnostics' Payables crashed by 7017.59% in 2023 and then skyrocketed by 15099.12% in 2025.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' Payables stood at $2.1 million in 2021, then fell by 12.85% to $1.8 million in 2022, then plummeted by 47.55% to $953000.0 in 2023, then soared by 139.14% to $2.3 million in 2024, then crashed by 53.66% to $1.1 million in 2025.
- Its Payables stands at $1.1 million for Q3 2025, versus $1.3 million for Q2 2025 and $2.3 million for Q1 2025.